Metabolic Syndrome - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509248044

Publication Date:

September 18, 2024

Pages:

133

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Metabolic syndrome is a cluster of conditions 鈥� increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels 鈥� that occur together, increasing your risk of heart disease, stroke and diabetes.
The global market for Metabolic Syndrome was estimated to be worth US$ 23890 million in 2023 and is forecast to a readjusted size of US$ 34940 million by 2030 with a CAGR of 5.1% during the forecast period 2024-2030
One of the upcoming trends gaining traction in the market is the increasing focus on oral insulin therapies. Till now, insulin injections were mostly administered through subcutaneous tissues, but this route of application is associated with risk of infection and hypersensitivity reactions, emboli, high cost, and injection site pain. Also, several needle-phobic individuals hesitate to adopt this route of administration. This paved the way for extensive research in the development of oral insulin. The oral form of insulin prevents the unpleasantness of insulin injections and other complications associated with the existing therapies. Moreover, oral administration of insulin ensures increased patient comfort and compliance, reduced risk of infection, simpler application, and is cost-effective.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Metabolic Syndrome, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Metabolic Syndrome by region & country, by Type, and by Application.
The Metabolic Syndrome market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Syndrome.
麻豆原创 Segmentation
By Company
Novo Nordisk
Sanofi
Merck
AstraZeneca
Eli Lily
AbbVie
Actelion Pharmaceuticals
Adocia
Aegerion Pharmaceuticals
Akros Pharma
Alnylam Pharmaceuticals
Amarin
nAmgen
Amicus Therapeutics
Arbutus Biopharma
Segment by Type:
Diabetes
Obesity
Hypercholesterolemia
Lysosomal storage diseases
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Metabolic Syndrome manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Metabolic Syndrome in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Metabolic Syndrome in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Metabolic Syndrome Product Introduction
1.2 Global Metabolic Syndrome 麻豆原创 Size Forecast
1.3 Metabolic Syndrome 麻豆原创 Trends & Drivers
1.3.1 Metabolic Syndrome Industry Trends
1.3.2 Metabolic Syndrome 麻豆原创 Drivers & Opportunity
1.3.3 Metabolic Syndrome 麻豆原创 Challenges
1.3.4 Metabolic Syndrome 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Metabolic Syndrome Players Revenue Ranking (2023)
2.2 Global Metabolic Syndrome Revenue by Company (2019-2024)
2.3 Key Companies Metabolic Syndrome Manufacturing Base Distribution and Headquarters
2.4 Key Companies Metabolic Syndrome Product Offered
2.5 Key Companies Time to Begin Mass Production of Metabolic Syndrome
2.6 Metabolic Syndrome 麻豆原创 Competitive Analysis
2.6.1 Metabolic Syndrome 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Metabolic Syndrome Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Syndrome as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Diabetes
3.1.2 Obesity
3.1.3 Hypercholesterolemia
3.1.4 Lysosomal storage diseases
3.2 Global Metabolic Syndrome Sales Value by Type
3.2.1 Global Metabolic Syndrome Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Metabolic Syndrome Sales Value, by Type (2019-2030)
3.2.3 Global Metabolic Syndrome Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Metabolic Syndrome Sales Value by Application
4.2.1 Global Metabolic Syndrome Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Metabolic Syndrome Sales Value, by Application (2019-2030)
4.2.3 Global Metabolic Syndrome Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Metabolic Syndrome Sales Value by Region
5.1.1 Global Metabolic Syndrome Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Metabolic Syndrome Sales Value by Region (2019-2024)
5.1.3 Global Metabolic Syndrome Sales Value by Region (2025-2030)
5.1.4 Global Metabolic Syndrome Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Metabolic Syndrome Sales Value, 2019-2030
5.2.2 North America Metabolic Syndrome Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Metabolic Syndrome Sales Value, 2019-2030
5.3.2 Europe Metabolic Syndrome Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Metabolic Syndrome Sales Value, 2019-2030
5.4.2 Asia Pacific Metabolic Syndrome Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Metabolic Syndrome Sales Value, 2019-2030
5.5.2 South America Metabolic Syndrome Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Metabolic Syndrome Sales Value, 2019-2030
5.6.2 Middle East & Africa Metabolic Syndrome Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Metabolic Syndrome Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Metabolic Syndrome Sales Value
6.3 United States
6.3.1 United States Metabolic Syndrome Sales Value, 2019-2030
6.3.2 United States Metabolic Syndrome Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Metabolic Syndrome Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Metabolic Syndrome Sales Value, 2019-2030
6.4.2 Europe Metabolic Syndrome Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Metabolic Syndrome Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Metabolic Syndrome Sales Value, 2019-2030
6.5.2 China Metabolic Syndrome Sales Value by Type (%), 2023 VS 2030
6.5.3 China Metabolic Syndrome Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Metabolic Syndrome Sales Value, 2019-2030
6.6.2 Japan Metabolic Syndrome Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Metabolic Syndrome Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Metabolic Syndrome Sales Value, 2019-2030
6.7.2 South Korea Metabolic Syndrome Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Metabolic Syndrome Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Metabolic Syndrome Sales Value, 2019-2030
6.8.2 Southeast Asia Metabolic Syndrome Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Metabolic Syndrome Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Metabolic Syndrome Sales Value, 2019-2030
6.9.2 India Metabolic Syndrome Sales Value by Type (%), 2023 VS 2030
6.9.3 India Metabolic Syndrome Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Novo Nordisk
7.1.1 Novo Nordisk Profile
7.1.2 Novo Nordisk Main Business
7.1.3 Novo Nordisk Metabolic Syndrome Products, Services and Solutions
7.1.4 Novo Nordisk Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.1.5 Novo Nordisk Recent Developments
7.2 Sanofi
7.2.1 Sanofi Profile
7.2.2 Sanofi Main Business
7.2.3 Sanofi Metabolic Syndrome Products, Services and Solutions
7.2.4 Sanofi Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.2.5 Sanofi Recent Developments
7.3 Merck
7.3.1 Merck Profile
7.3.2 Merck Main Business
7.3.3 Merck Metabolic Syndrome Products, Services and Solutions
7.3.4 Merck Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.3.5 AstraZeneca Recent Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Profile
7.4.2 AstraZeneca Main Business
7.4.3 AstraZeneca Metabolic Syndrome Products, Services and Solutions
7.4.4 AstraZeneca Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.4.5 AstraZeneca Recent Developments
7.5 Eli Lily
7.5.1 Eli Lily Profile
7.5.2 Eli Lily Main Business
7.5.3 Eli Lily Metabolic Syndrome Products, Services and Solutions
7.5.4 Eli Lily Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.5.5 Eli Lily Recent Developments
7.6 AbbVie
7.6.1 AbbVie Profile
7.6.2 AbbVie Main Business
7.6.3 AbbVie Metabolic Syndrome Products, Services and Solutions
7.6.4 AbbVie Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.6.5 AbbVie Recent Developments
7.7 Actelion Pharmaceuticals
7.7.1 Actelion Pharmaceuticals Profile
7.7.2 Actelion Pharmaceuticals Main Business
7.7.3 Actelion Pharmaceuticals Metabolic Syndrome Products, Services and Solutions
7.7.4 Actelion Pharmaceuticals Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.7.5 Actelion Pharmaceuticals Recent Developments
7.8 Adocia
7.8.1 Adocia Profile
7.8.2 Adocia Main Business
7.8.3 Adocia Metabolic Syndrome Products, Services and Solutions
7.8.4 Adocia Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.8.5 Adocia Recent Developments
7.9 Aegerion Pharmaceuticals
7.9.1 Aegerion Pharmaceuticals Profile
7.9.2 Aegerion Pharmaceuticals Main Business
7.9.3 Aegerion Pharmaceuticals Metabolic Syndrome Products, Services and Solutions
7.9.4 Aegerion Pharmaceuticals Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.9.5 Aegerion Pharmaceuticals Recent Developments
7.10 Akros Pharma
7.10.1 Akros Pharma Profile
7.10.2 Akros Pharma Main Business
7.10.3 Akros Pharma Metabolic Syndrome Products, Services and Solutions
7.10.4 Akros Pharma Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.10.5 Akros Pharma Recent Developments
7.11 Alnylam Pharmaceuticals
7.11.1 Alnylam Pharmaceuticals Profile
7.11.2 Alnylam Pharmaceuticals Main Business
7.11.3 Alnylam Pharmaceuticals Metabolic Syndrome Products, Services and Solutions
7.11.4 Alnylam Pharmaceuticals Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.11.5 Alnylam Pharmaceuticals Recent Developments
7.12 Amarin
7.12.1 Amarin Profile
7.12.2 Amarin Main Business
7.12.3 Amarin Metabolic Syndrome Products, Services and Solutions
7.12.4 Amarin Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.12.5 Amarin Recent Developments
7.13 nAmgen
7.13.1 nAmgen Profile
7.13.2 nAmgen Main Business
7.13.3 nAmgen Metabolic Syndrome Products, Services and Solutions
7.13.4 nAmgen Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.13.5 nAmgen Recent Developments
7.14 Amicus Therapeutics
7.14.1 Amicus Therapeutics Profile
7.14.2 Amicus Therapeutics Main Business
7.14.3 Amicus Therapeutics Metabolic Syndrome Products, Services and Solutions
7.14.4 Amicus Therapeutics Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.14.5 Amicus Therapeutics Recent Developments
7.15 Arbutus Biopharma
7.15.1 Arbutus Biopharma Profile
7.15.2 Arbutus Biopharma Main Business
7.15.3 Arbutus Biopharma Metabolic Syndrome Products, Services and Solutions
7.15.4 Arbutus Biopharma Metabolic Syndrome Revenue (US$ Million) & (2019-2024)
7.15.5 Arbutus Biopharma Recent Developments
8 Industry Chain Analysis
8.1 Metabolic Syndrome Industrial Chain
8.2 Metabolic Syndrome Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Metabolic Syndrome Sales Model
8.5.2 Sales Channel
8.5.3 Metabolic Syndrome Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Novo Nordisk
Sanofi
Merck
AstraZeneca
Eli Lily
AbbVie
Actelion Pharmaceuticals
Adocia
Aegerion Pharmaceuticals
Akros Pharma
Alnylam Pharmaceuticals
Amarin
nAmgen
Amicus Therapeutics
Arbutus Biopharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.